Nasdaq: $27.09 (+0.50) | AIM: £3.87 (+0.23)
2000
FOUNDED
600+
SCIENTIFIC TEAM
BASED IN CHINA, US,
EUROPE & AUSTRALIA
420
DEDICATED ONCOLOGY
COMMERCIAL TEAM
IN CHINA
10
IN-HOUSE DISCOVERED
CLINICAL STAGE DRUG CANDIDATES
2
APPROVED PRODUCTS
IN CHINA
1
NDA SUBMISSION
INITIATED IN THE US
~40
CLINICAL TRIALS
AROUND THE GLOBE
HCM
NASDAQ &
LONDON AIM

OUR SCIENCE

Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.

R&D Philosophy Pipeline Products

Events, Circulars And Forms


Bank of America 2021 Health Care Conference 2021-05-11
Goldman Sachs Global Healthcare Conference Webcast 2021-06-08 - 2021-06-11
Jefferies Virtual Global Healthcare Conference 2021-06-01 - 2021-06-04